The pan-FGFR inhibitor infigratinib worked effectively in most mutant ICC cells compared to the control and was more efficient than another FGFR inhibitor, pemigatinib, which exhibited better sensitivity only in Tgfbr2- and Cul3-mutant cells. The gene discussed is TGFBR2; the disease is intrahepatic cholangiocarcinoma.